186 related articles for article (PubMed ID: 32449964)
1. Impact of detectable measurable residual disease on umbilical cord blood transplantation.
Baron F; Labopin M; Ruggeri A; Sierra J; Robinson S; Labussière-Wallet H; Potter M; Ribera JM; Deconinck E; Rambaldi A; Rohrlich PS; de Revel T; Gluckman E; Nagler A; Mohty M
Am J Hematol; 2020 Sep; 95(9):1057-1065. PubMed ID: 32449964
[TBL] [Abstract][Full Text] [Related]
2. Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT.
Pavlů J; Labopin M; Niittyvuopio R; Socié G; Yakoub-Agha I; Wu D; Remenyi P; Passweg J; Beelen DW; Aljurf M; Kröger N; Labussière-Wallet H; Perić Z; Giebel S; Nagler A; Mohty M
J Hematol Oncol; 2019 Oct; 12(1):108. PubMed ID: 31647022
[TBL] [Abstract][Full Text] [Related]
3. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A
Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272
[TBL] [Abstract][Full Text] [Related]
4. The impact of pre-transplant minimal residual disease on outcome of intensified myeloablative cord blood transplant for acute myeloid leukemia in first or second complete remission.
Zheng C; Zhu X; Tang B; Zhang L; Geng L; Liu H; Sun Z
Leuk Lymphoma; 2016; 57(6):1398-405. PubMed ID: 26690538
[TBL] [Abstract][Full Text] [Related]
5. Impact of pretransplant minimal residual disease after cord blood transplantation for childhood acute lymphoblastic leukemia in remission: an Eurocord, PDWP-EBMT analysis.
Ruggeri A; Michel G; Dalle JH; Caniglia M; Locatelli F; Campos A; de Heredia CD; Mohty M; Hurtado JM; Bierings M; Bittencourt H; Mauad M; Purtill D; Cunha R; Kabbara N; Gluckman E; Labopin M; Peters C; Rocha V
Leukemia; 2012 Dec; 26(12):2455-61. PubMed ID: 22555150
[TBL] [Abstract][Full Text] [Related]
6. Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia.
Appelbaum FR
Best Pract Res Clin Haematol; 2013 Sep; 26(3):279-84. PubMed ID: 24309531
[TBL] [Abstract][Full Text] [Related]
7. Minimal residual disease status predicts outcome of acute myeloid leukaemia patients undergoing T-cell replete haploidentical transplantation. An analysis from the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT).
Canaani J; Labopin M; Huang XJ; Ciceri F; Van Lint MT; Bruno B; Santarone S; Diez-Martin JL; Blaise D; Chiusolo P; Wu D; Mohty M; Nagler A
Br J Haematol; 2018 Nov; 183(3):411-420. PubMed ID: 30117144
[TBL] [Abstract][Full Text] [Related]
8. Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantation.
Devillier R; Harbi S; Fürst S; Crocchiolo R; El-Cheikh J; Castagna L; Etienne A; Calmels B; Lemarie C; Prebet T; Granata A; Charbonnier A; Rey J; Chabannon C; Faucher C; Vey N; Blaise D
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1560-5. PubMed ID: 24933658
[TBL] [Abstract][Full Text] [Related]
9. Impact of minimal residual disease on outcomes after umbilical cord blood transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia: an analysis on behalf of Eurocord, Cord Blood Committee and the Acute Leukaemia working party of the European group for Blood and Marrow Transplantation.
Tucunduva L; Ruggeri A; Sanz G; Furst S; Cornelissen J; Linkesch W; Mannone L; Ribera JM; Veelken H; Yakoub-Agha I; González Valentín ME; Schots R; Arcese W; Montesinos P; Labopin M; Gluckman E; Mohty M; Rocha V
Br J Haematol; 2014 Sep; 166(5):749-57. PubMed ID: 24961645
[TBL] [Abstract][Full Text] [Related]
10. Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study.
Zhao H; Wei J; Wei G; Luo Y; Shi J; Cui Q; Zhao M; Liang A; Zhang Q; Yang J; Li X; Chen J; Song X; Jing H; Li Y; Hao S; Wu W; Tan Y; Yu J; Zhao Y; Lai X; Yin ETS; Wei Y; Li P; Huang J; Wang T; Blaise D; Xiao L; Chang AH; Nagler A; Mohty M; Huang H; Hu Y
J Hematol Oncol; 2020 May; 13(1):42. PubMed ID: 32366260
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia.
Candoni A; De Marchi F; Zanini F; Zannier ME; Simeone E; Toffoletti E; Chiarvesio A; Cerno M; Filì C; Patriarca F; Fanin R
Exp Hematol; 2017 May; 49():25-33. PubMed ID: 28159598
[TBL] [Abstract][Full Text] [Related]
12. Minimal residual disease status determined by multiparametric flow cytometry pretransplantation predicts the outcome of patients with ALL receiving unmanipulated haploidentical allografts.
Zhao XS; Liu YR; Xu LP; Wang Y; Zhang XH; Chen H; Chen YH; Han W; Sun YQ; Yan CH; Mo XD; Wang YZ; Fan QZ; Wang XY; Liu KY; Huang XJ; Chang YJ
Am J Hematol; 2019 May; 94(5):512-521. PubMed ID: 30680765
[TBL] [Abstract][Full Text] [Related]
13. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R
Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
[TBL] [Abstract][Full Text] [Related]
14. Clinical separation of cGvHD and GvL and better GvHD-free/relapse-free survival (GRFS) after unrelated cord blood transplantation for AML.
Zheng CC; Zhu XY; Tang BL; Zhang XH; Zhang L; Geng LQ; Liu HL; Sun ZM
Bone Marrow Transplant; 2017 Jan; 52(1):88-94. PubMed ID: 27376453
[TBL] [Abstract][Full Text] [Related]
15. [Minimal residual disease in adults with Philadelphia chromosome negative acute lymphoblastic leukemia in high-risk].
Li ZR; Zhao T; Liu YR; Wang YZ; Xu LP; Zhang XH; Wang Y; Jiang H; Chen YY; Chen H; Han W; Yan CH; Wang J; Jia JS; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2019 Jul; 40(7):554-560. PubMed ID: 32397017
[No Abstract] [Full Text] [Related]
16. Measurable residual disease (MRD) status before allogeneic hematopoietic cell transplantation impact on secondary acute myeloid leukemia outcome. A Study from the Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT).
Maffini E; Labopin M; Beelen DW; Kroeger N; Arat M; Wilson KMO; Bay JO; Ganser A; Martin H; Passweg J; Kottaridis PD; Yakoub-Agha I; Porras RP; Wagner EM; Esteve J; Lanza F; Nagler A; Mohty M
Bone Marrow Transplant; 2022 Oct; 57(10):1556-1563. PubMed ID: 35835997
[TBL] [Abstract][Full Text] [Related]
17. Myeloablative Unrelated Cord Blood Transplantation in Adolescents and Young Adults with Acute Leukemia.
Hayashi H; Volt F; Sanz J; Petersen E; Dhedin N; Hough R; Milpied N; Angelucci E; Yakoub-Agha I; Michallet M; Michel G; Aljurf M; Kenzey C; Rocha V; Dalle JH; Bader P; Ruggeri A; Gluckman E;
Biol Blood Marrow Transplant; 2019 Dec; 25(12):2438-2446. PubMed ID: 31394275
[TBL] [Abstract][Full Text] [Related]
18. Highlighting the Prognostic Importance of Measurable Residual Disease Among Acute Myeloid Leukemia Risk Factors.
Narlı Özdemir Z; Şahin U; Dalva K; Baltacı MA; Uslu A; Öztürk C; Cengiz Seval G; Toprak SK; Kurt Yüksel M; Topçuoğlu P; Arslan Ö; Özcan M; Beksaç M; İlhan O; Gürman G; Civriz Bozdağ S
Turk J Haematol; 2021 Jun; 38(2):111-118. PubMed ID: 33112099
[TBL] [Abstract][Full Text] [Related]
19. Unrelated cord blood transplantation in adult and pediatric acute lymphoblastic leukemia: effect of minimal residual disease on relapse and survival.
Bachanova V; Burke MJ; Yohe S; Cao Q; Sandhu K; Singleton TP; Brunstein CG; Wagner JE; Verneris MR; Weisdorf DJ
Biol Blood Marrow Transplant; 2012 Jun; 18(6):963-8. PubMed ID: 22430088
[TBL] [Abstract][Full Text] [Related]
20. Association Between Measurable Residual Disease in Patients With Intermediate-Risk Acute Myeloid Leukemia and First Remission, Treatment, and Outcomes.
Yu S; Fan Z; Ma L; Wang Y; Huang F; Zhang Q; Huang J; Wang S; Xu N; Xuan L; Xiong M; Han L; Sun Z; Zhang H; Liu H; Yu G; Shi P; Xu J; Wu M; Guo Z; Xiong Y; Duan C; Sun J; Liu Q; Zhang Y
JAMA Netw Open; 2021 Jul; 4(7):e2115991. PubMed ID: 34232303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
